CONVENIENT ONCE-DAILY DOSING*

**IMPORTANT SAFETY INFORMATION:**
Use of this product at doses above the recommended 2.27mg/lb (5mg/kg) in puppies less than seven months of age has been associated with serious adverse reactions, including death. Due to tablet sizes and scoring, dogs weighing less than 12.5 lb (5.7 kg) cannot be accurately dosed. Refer to the prescribing information for complete details or visit [www.PREVICOX.com](http://www.PREVICOX.com).

For Questions please call the Boehringer Ingelheim AH USA Veterinary Technical Solutions Team at [1-888-637-4251](tel:1-888-637-4251) or contact your Boehringer Ingelheim AH USA Representative.

---

<table>
<thead>
<tr>
<th>DOG BODY WEIGHT</th>
<th># of Tablets/Daily Dose</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>57mg</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1 tablet</strong></td>
<td></td>
<td>&gt;71 - 120 lbs. &gt;32.2 - 54.4 kg</td>
</tr>
<tr>
<td><strong>1 1/2 tablets</strong></td>
<td></td>
<td>&gt;120 - 160 lbs. &gt;54.4 - 72.6 kg</td>
</tr>
<tr>
<td><strong>2 tablets</strong></td>
<td></td>
<td>&gt;160 - 240 lbs. &gt;72.6 - 108.9 kg</td>
</tr>
</tbody>
</table>

*Dose is 5 mg/kg. These tables are a suggested practical dosing guide.
While the active metabolite of PREVICOX (firocoxib) is approximately 40% when administered as a 5 mg/kg dose to adult dogs, firocoxib is rapidly cleared from the blood. The total plasma clearance rate of PREVICOX (firocoxib) is 1.3 mg/kg/h. The plasma protein binding of PREVICOX (firocoxib) is 99% and the molecular weight is 348.42. This structural formula is shown below:

![Structural formula of firocoxib](image)

**Pharmacokinetics**

Firocoxib is a nonsteroidal anti-inflammatory drug (NSAID) of the cyclooxygenase-2 (COX-2) selectivity class. PREVICOX Chewable Tablets are the only available COX-2 selective NSAID approved for use in dogs. Firocoxib is metabolized by the liver and eliminated primarily in the urine. The plasma elimination half-life of firocoxib is 20 hours in dogs. Approximately 60% of administered firocoxib is excreted unchanged in the urine, and 10% is excreted in the feces. The major metabolite of firocoxib is a glucuronide conjugate, which is also excreted in the urine. The primary route of excretion of the glucuronide conjugate is in the urine. The major metabolite is less active than firocoxib in COX-2 enzyme inhibition assays.

**Indications**

PREVICOX Chewable Tablets are indicated for the management of pain associated with orthopedic surgery and soft-tissue surgery in dogs.

**Contraindications**

PREVICOX Chewable Tablets are contraindicated in dogs with known hypersensitivity (e.g., previous adverse reactions) or known aspirin intolerance. PREVICOX Chewable Tablets are contraindicated in dogs with a history of gastrointestinal hemorrhage, hematemesis, melena, or hematochezia. In addition, PREVICOX Chewable Tablets are contraindicated in dogs with a history of excessive bleeding, hematuria, bleeding disorders, or a history of hemostatic dysfunction.

**Warnings**

The safe use of PREVICOX Chewable Tablets in pregnant, lactating or breeding dogs has not been evaluated. It is not known whether firocoxib is excreted in milk. Due to its known or potential persistence in fat, firocoxib is likely to be excreted in milk. The decision to administer this medication to a nursing mother should carefully weigh the potential benefits against the possible risks to the nursing dog.

**Adverse Reactions**

Adverse reactions have occurred in dogs treated with PREVICOX Chewable Tablets. The most frequently reported adverse reactions in dogs treated with PREVICOX Chewable Tablets are vomiting, diarrhea, anorexia, lethargy, weakness, and pyrexia. In a target animal safety study, 5% of dogs treated with PREVICOX Chewable Tablets had vomiting, diarrhea, or anorexia. These adverse reactions were similar in incidence to those seen in control dogs and were not considered drug-related.

**Adverse Reactions and Animal Health**

In a target animal safety study, firocoxib was administered orally to healthy adult dogs at 2.27 mg/lb (5.0 mg/kg) for 22 days. All dogs survived to the end of the study. Three of five dogs (60%) given PREVICOX Chewable Tablets at a dose of 2.27 mg/lb (5.0 mg/kg) orally developed gastrointestinal ulceration, peritonitis, bleeding, nausea, decreased appetite, vomiting, pyrexia, and loss of weight. One of these five dogs also developed pyrexia and vomiting. In a separate field study, five dogs were treated with PREVICOX Chewable Tablets at a dose of 2.27 mg/lb (5.0 mg/kg) orally for 22 days. All dogs survived to the end of the study. Three of five dogs (60%) developed vomiting, diarrhea, pyrexia, and anorexia. One of these five dogs also developed vomiting, diarrhea, pyrexia, and anorexia. These adverse reactions were similar in incidence to those seen in control dogs and were not considered drug-related.

**Adverse Reactions and Animal Health**

In a target animal safety study, firocoxib was administered orally to healthy adult dogs at 2.27 mg/lb (5.0 mg/kg) for 22 days. All dogs survived to the end of the study. Three of five dogs (60%) given PREVICOX Chewable Tablets at a dose of 2.27 mg/lb (5.0 mg/kg) orally developed gastrointestinal ulceration, peritonitis, bleeding, nausea, decreased appetite, vomiting, pyrexia, and loss of weight. One of these five dogs also developed pyrexia and vomiting. In a separate field study, five dogs were treated with PREVICOX Chewable Tablets at a dose of 2.27 mg/lb (5.0 mg/kg) orally for 22 days. All dogs survived to the end of the study. Three of five dogs (60%) developed vomiting, diarrhea, pyrexia, and anorexia. One of these five dogs also developed vomiting, diarrhea, pyrexia, and anorexia. These adverse reactions were similar in incidence to those seen in control dogs and were not considered drug-related.

**Adverse Reactions and Animal Health**

In a target animal safety study, firocoxib was administered orally to healthy adult dogs at 2.27 mg/lb (5.0 mg/kg) for 22 days. All dogs survived to the end of the study. Three of five dogs (60%) given PREVICOX Chewable Tablets at a dose of 2.27 mg/lb (5.0 mg/kg) orally developed gastrointestinal ulceration, peritonitis, bleeding, nausea, decreased appetite, vomiting, pyrexia, and loss of weight. One of these five dogs also developed pyrexia and vomiting. In a separate field study, five dogs were treated with PREVICOX Chewable Tablets at a dose of 2.27 mg/lb (5.0 mg/kg) orally for 22 days. All dogs survived to the end of the study. Three of five dogs (60%) developed vomiting, diarrhea, pyrexia, and anorexia. One of these five dogs also developed vomiting, diarrhea, pyrexia, and anorexia. These adverse reactions were similar in incidence to those seen in control dogs and were not considered drug-related.

**Adverse Reactions and Animal Health**

In a target animal safety study, firocoxib was administered orally to healthy adult dogs at 2.27 mg/lb (5.0 mg/kg) for 22 days. All dogs survived to the end of the study. Three of five dogs (60%) given PREVICOX Chewable Tablets at a dose of 2.27 mg/lb (5.0 mg/kg) orally developed gastrointestinal ulceration, peritonitis, bleeding, nausea, decreased appetite, vomiting, pyrexia, and loss of weight. One of these five dogs also developed pyrexia and vomiting. In a separate field study, five dogs were treated with PREVICOX Chewable Tablets at a dose of 2.27 mg/lb (5.0 mg/kg) orally for 22 days. All dogs survived to the end of the study. Three of five dogs (60%) developed vomiting, diarrhea, pyrexia, and anorexia. One of these five dogs also developed vomiting, diarrhea, pyrexia, and anorexia. These adverse reactions were similar in incidence to those seen in control dogs and were not considered drug-related.

**Adverse Reactions and Animal Health**

In a target animal safety study, firocoxib was administered orally to healthy adult dogs at 2.27 mg/lb (5.0 mg/kg) for 22 days. All dogs survived to the end of the study. Three of five dogs (60%) given PREVICOX Chewable Tablets at a dose of 2.27 mg/lb (5.0 mg/kg) orally developed gastrointestinal ulceration, peritonitis, bleeding, nausea, decreased appetite, vomiting, pyrexia, and loss of weight. One of these five dogs also developed pyrexia and vomiting. In a separate field study, five dogs were treated with PREVICOX Chewable Tablets at a dose of 2.27 mg/lb (5.0 mg/kg) orally for 22 days. All dogs survived to the end of the study. Three of five dogs (60%) developed vomiting, diarrhea, pyrexia, and anorexia. One of these five dogs also developed vomiting, diarrhea, pyrexia, and anorexia. These adverse reactions were similar in incidence to those seen in control dogs and were not considered drug-related.

**Adverse Reactions and Animal Health**

In a target animal safety study, firocoxib was administered orally to healthy adult dogs at 2.27 mg/lb (5.0 mg/kg) for 22 days. All dogs survived to the end of the study. Three of five dogs (60%) given PREVICOX Chewable Tablets at a dose of 2.27 mg/lb (5.0 mg/kg) orally developed gastrointestinal ulceration, peritonitis, bleeding, nausea, decreased appetite, vomiting, pyrexia, and loss of weight. One of these five dogs also developed pyrexia and vomiting. In a separate field study, five dogs were treated with PREVICOX Chewable Tablets at a dose of 2.27 mg/lb (5.0 mg/kg) orally for 22 days. All dogs survived to the end of the study. Three of five dogs (60%) developed vomiting, diarrhea, pyrexia, and anorexia. One of these five dogs also developed vomiting, diarrhea, pyrexia, and anorexia. These adverse reactions were similar in incidence to those seen in control dogs and were not considered drug-related.

**Adverse Reactions and Animal Health**

In a target animal safety study, firocoxib was administered orally to healthy adult dogs at 2.27 mg/lb (5.0 mg/kg) for 22 days. All dogs survived to the end of the study. Three of five dogs (60%) given PREVICOX Chewable Tablets at a dose of 2.27 mg/lb (5.0 mg/kg) orally developed gastrointestinal ulceration, peritonitis, bleeding, nausea, decreased appetite, vomiting, pyrexia, and loss of weight. One of these five dogs also developed pyrexia and vomiting. In a separate field study, five dogs were treated with PREVICOX Chewable Tablets at a dose of 2.27 mg/lb (5.0 mg/kg) orally for 22 days. All dogs survived to the end of the study. Three of five dogs (60%) developed vomiting, diarrhea, pyrexia, and anorexia. One of these five dogs also developed vomiting, diarrhea, pyrexia, and anorexia. These adverse reactions were similar in incidence to those seen in control dogs and were not considered drug-related.